from https://www.beingpatient.com/vaccine-for-alzheimers/ by Emily Woodruff January 17th, 2019
A Dublin based United Neurosciences Company has been pursuing a vaccine trial even though some past vaccine trials ended in brain swelling and cancellation. This drug called UB-311 is completing it’s phase 2a Clinical Study. The 2b study for efficacy and then Phase 3 for proper potency will follow if all goes well.
Phase 2a consisted of 42 patients with mild cognitive impairment (MCI) who were most likely in the early stages of Alzheimer’s. They were divided into 3 groups: placebo, vaccine shots x3 and then a booster every 3 months, and the vaccine x3 and a booster every 6 months.
Results showed that 96% of the participants had improved cognition and lower levels of beta-amyloid, the protein responsible for the damaging plaques. Although promising, the small number of patients in the trial made the results statistically insignificant. I will be looking for the results of the 2b and Phase 3 trial as they are begun and finished. The results won’t be available for years. And then there must be guidelines to determine who would benefit most from the vaccine if it proves effective.